1. Home
  2. ATEN vs CAPR Comparison

ATEN vs CAPR Comparison

Compare ATEN & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo A10 Networks Inc.

ATEN

A10 Networks Inc.

HOLD

Current Price

$20.60

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$22.51

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATEN
CAPR
Founded
2004
2005
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.3B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
ATEN
CAPR
Price
$20.60
$22.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$22.67
$41.38
AVG Volume (30 Days)
921.6K
1.0M
Earning Date
02-04-2026
03-18-2026
Dividend Yield
1.16%
N/A
EPS Growth
N/A
N/A
EPS
0.57
N/A
Revenue
$290,557,000.00
$11,130,509.00
Revenue This Year
$9.40
N/A
Revenue Next Year
$7.65
$17,308.50
P/E Ratio
$36.32
N/A
Revenue Growth
11.03
N/A
52 Week Low
$13.81
$4.30
52 Week High
$21.90
$40.37

Technical Indicators

Market Signals
Indicator
ATEN
CAPR
Relative Strength Index (RSI) 66.40 49.65
Support Level $20.17 $23.23
Resistance Level $21.31 $25.45
Average True Range (ATR) 0.78 1.39
MACD 0.29 -0.01
Stochastic Oscillator 79.60 64.01

Price Performance

Historical Comparison
ATEN
CAPR

About ATEN A10 Networks Inc.

A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: